Investment
Features
FeesSafety
Academy
More
Pluang+

Alphamin Resources offers a promising buy with stable tin mines and growth potential in DRC.

Analyst Insights
10 Oct 2026
Seeking Alpha
View Source
Bullish
Alphamin Resources offers a promising buy with stable tin mines and growth potential in DRC.

Alphamin Resources Corp. operates two profitable tin mines in the Democratic Republic of Congo and is focusing on exploration around its Bisie resource, offering speculative growth potential. The company's current operations are stable and profitable, which reduces downside risk despite the speculative nature of future expansion. The investment case is supported by favorable risk/reward, market tailwinds, and experienced management in the region, making Alphamin a compelling buy opportunity for investors seeking exposure to tin mining in Central Africa.

Alphamin Resources, a tin mining company with speculative growth potential, is presented here with Pluang's market context. For readers following US stocks on Pluang as of Oct 10, 2026 14:01 WIB: out of 150 priced stocks, 101 rose and 48 fell. Moderna (MRNA) gained 14.21% at USD 225.00 with a typical hold time of 59 days, contrasting with AT&T (T) and Verizon (VZ), which fell 10.87% and 10.14% respectively, both showing strong buy order activity at 95% and hold times over 100 days.

More News

Sigenergy debuts AI-powered energy solutions and new partnerships at Malaysia's IGEM 2026.

Sigenergy debuts AI-powered energy solutions and new partnerships at Malaysia's IGEM 2026.

At Malaysia's IGEM 2026, Sigenergy showcased its latest AI-driven energy technologies, including smart storage and inverter systems, highlighting its role in advancing sustainable energy. The company also signed MOUs with local partners Milieu and YT...

Market News
Bullish
2 hours ago
Entrada Therapeutics rated Buy with $8.50 target, expects higher drug dosing results in 2027.

Entrada Therapeutics rated Buy with $8.50 target, expects higher drug dosing results in 2027.

Entrada Therapeutics is rated Buy with a fair value of $8.50, implying about 52% upside from the current $5.61 price. The company’s Duchenne muscular dystrophy drug ENTR-601-44 showed a disappointing initial increase in dystrophin, but this is attrib...

Analyst Insights
Neutral
4 hours ago
Ten-year Treasury yields hit 5.36% amid systemic debt concerns and strong stock market gains.

Ten-year Treasury yields hit 5.36% amid systemic debt concerns and strong stock market gains.

Ten-year U.S. Treasury yields reached 5.36% intraday, reflecting growing systemic sovereign debt issues. Despite these concerns, the stock market showed strength with the S&P 500 rising 1.2% and the Dow gaining 0.9%, supported by a 43-week expansion ...

Market News
Neutral
4 hours ago
Pump.fun's token buyback drops as daily revenue falls 16%, impacting price support until April 2027.

Pump.fun's token buyback drops as daily revenue falls 16%, impacting price support until April 2027.

Pump.fun's daily revenue, which funds half of its token buyback and burn program, fell 16% from $1.89 million on October 5 to $1.59 million on October 9, causing the token price to drop 16.8% from its weekly high. The buyback program, running until A...

Protocol Fundamentals
Bearish
4 hours ago
Cardano vote on cutting stake pool fee from 170 to 75 ADA falls short at 34.45% approval, deadline Oct 11, 2026.

Cardano vote on cutting stake pool fee from 170 to 75 ADA falls short at 34.45% approval, deadline Oct 11, 2026.

A vote on Cardano proposes reducing the fixed minimum stake pool fee from 170 ADA to 75 ADA to help small pools remain viable amid declining block rewards. As of October 10, 2026, approval stands at 34.45% against a required 67%, with the vote closin...

Protocol Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App